Outcomes of patients with late relapse metastatic renal cell carcinoma treated with targeted therapies: A single-institution experience.

被引：0
|
作者：
Mandalapu, Kemal Kishore [1 ]
Matrana, Marc Ryan [1 ]
Poosarla, Teja [1 ]
机构：
[1] Ochsner Med Ctr, New Orleans, LA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.498
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
498
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Outcomes Following Immunotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Single-Institution Experience
    Yalamanchali, A.
    Yang, K.
    Schwartzman, L.
    Campbell, S. R.
    Silver, N. L.
    Woody, N. M.
    Griffith, C.
    Cracolici, V.
    Chute, D.
    Koyfman, S.
    Geiger, J. L.
    Yilmaz, E.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (05): : E40 - E40
  • [22] Renal cell carcinoma metastatic to the pancreas: A single-institution series and review of the literature
    Kassabian, A
    Stein, J
    Jabbour, N
    Parsa, K
    Skinner, D
    Parekh, D
    Cosenza, C
    Selby, R
    [J]. UROLOGY, 2000, 56 (02) : 211 - 215
  • [23] Prognostic factors for survival in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic therapies: Overall results of a large experience.
    Procopio, G.
    Verzoni, E.
    Iacovelli, R.
    Mattana, F.
    Guadalupi, V.
    Mariani, L.
    Stagni, S.
    Salvioni, R.
    Buzzoni, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies
    Bastin, Julie
    Werbrouck, Emilie
    Verbiest, Annelies
    Punie, Kevin
    Bechter, Oliver
    Woei-A-Jin, Feng Jung
    Wolter, Pascal
    Wildiers, Hans
    Lerut, Evelyne
    Dumez, Herlinde
    Decallonne, Brigitte
    Clement, Paul
    Vanderschueren, Dirk
    Albersen, Maarten
    Oyen, Raymond
    Schoffski, Patrick
    Beuselinck, Benoit
    [J]. ACTA CLINICA BELGICA, 2019, 74 (03) : 169 - 179
  • [25] Molecular profiles and response among metastatic renal cell carcinoma patients treated with targeted therapies
    Donskov, F.
    Pinto, C. A.
    Predoui, R.
    Kong, F.
    Fox, C.
    Georgsen, J.
    Skaarup, K.
    Perini, R.
    Steiniche, T.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S301 - S301
  • [26] Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma
    Nouhaud, F. X.
    Rebibo, J. -D.
    Blanchard, F.
    Sabourin, J. -C.
    Di Fiore, F.
    Pfister, C.
    [J]. PROGRES EN UROLOGIE, 2014, 24 (09): : 563 - 571
  • [27] Clinical outcomes of temporal bone squamous cell carcinoma: A single-institution experience
    Zheng, Yongbo
    Qiu, Ke
    Fu, Yangju
    Yang, Wenjie
    Cheng, Danni
    Rao, Yufang
    Mao, Minzi
    Song, Yao
    Xu, Wei
    Ren, Jianjun
    Zhao, Yu
    [J]. CANCER MEDICINE, 2023, 12 (05): : 5304 - 5311
  • [28] Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies
    Matrana, M. R.
    Duran, C.
    Shetty, A.
    Xiao, L.
    Atkinson, B. J.
    Corn, P.
    Pagliaro, L. C.
    Millikan, R. E.
    Charnsangave, C.
    Jonasch, E.
    Tannir, N. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (15) : 3169 - 3175
  • [29] Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience
    Korenbaum, Clement
    Pierard, Laure
    Thiery, Alicia
    Story, Fleur
    Lindner, Veronique
    Lang, Herve
    Kurtz, Jean-Emmanuel
    Barthelemy, Philippe
    [J]. CLINICAL GENITOURINARY CANCER, 2018, 16 (03) : E577 - E586
  • [30] Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies
    Cholley, Tiphaine
    Thiery-Vuillemin, Antoine
    Limat, Samuel
    Hugues, Marion
    Calcagno, Fabien
    Mouillet, Guillaume
    Anota, Amelie
    Nerich, Virginie
    [J]. CLINICAL GENITOURINARY CANCER, 2019, 17 (01) : E227 - E234
12345